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Age-specific genetic and antigenic 
variations of influenza A viruses in 
Hong Kong, 2013–2014
Peihua Cao1, Chit-Ming Wong1, Kwok-Hung Chan2, Xiling Wang3, King-Pan Chan1, 
Joseph Sriyal Malik Peiris4, Leo Lit-Man Poon4 & Lin Yang5
Age-specific genetic and antigenic variations of influenza viruses have not been documented in tropical 
and subtropical regions. We implemented a systematic surveillance program in two tertiary hospitals 
in Hong Kong Island, to collect 112 A(H1N1)pdm09 and 254 A(H3N2) positive specimens from 2013 
to 2014. Of these, 56 and 72 were identified as genetic variants of the WHO recommended vaccine 
composition strains, respectively. A subset of these genetic variants was selected for hemagglutination-
inhibition (HI) tests, but none appeared to be antigenic variants of the vaccine composition strains. We 
also found that genetic and antigenicity variations were similar across sex and age groups of ≤18 yrs,  
18 to 65 yrs, and ≥65 yrs. Our findings suggest that none of the age groups led other age groups in 
genetic evolution of influenza virus A strains. Future studies from different regions and longer study 
periods are needed to further investigate the age and sex heterogeneity of influenza viruses.
Influenza viruses undergo frequent antigenic drift, and cause winter epidemics in temperate regions and 
year-long circulation in tropical and subtropical regions. The World Health Organization (WHO) has established 
the Global Influenza Surveillance and Response System (GISRS) to track the antigenic change of influenza viruses 
worldwide, with the aim of guiding the selection of suitable influenza candidate vaccine viruses1. In Hong Kong, 
the influenza surveillance network managed by the Department of Health routinely selected potentially drifted 
specimens for genetic and antigenic characterization. However, temporal variations of genetic and antigenicity 
characteristics have never been studied, largely due to the relatively small number of specimens which were sub-
jectively selected based on antigenic drifts and disease severity, rather than from a representative sample of strains 
currently circulating in the whole population.
Recent large-scale phylogenetic studies have demonstrated co-circulation of different influenza strains in 
tropical and subtropical regions of Southeast and East Asia, but it remains controversial whether novel viruses 
first originated from these regions2–4. Age discrepancy in susceptibility to different virus subtypes has also been 
reported5. For example, children were found more likely to be infected by A(H1N1)pdm09 as compared to adults, 
whereas A(H3N2) tended to affect more adults. However, age information has seldom been incorporated into 
genetic and antigenic surveillance, and to this date few studies have assessed the age difference in terms of genetic 
and antigenic variations.
In this study, we implemented a systematic surveillance program during 2013–2014, to randomly select a 
sample of positive specimens of children (aged below 18 years) and adults, from two tertiary hospitals in the 
Hong Kong Island each week. The systematically collected specimens were expected representative of concurrent 
circulating strains in the population6 and could also allow the investigation of temporal variations of genetic and 
antigenicity characteristics of concurrently circulating influenza viruses.
Results
Figure 1 shows the total number of specimens collected by the Queen Mary Hospital microbiology labo-
ratory each week and also the number of specimens selected for sequencing in our study. The demographic 
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characteristics of patients whose specimens were selected for sequencing and Hemagglutinin Inhibition (HI) tests 
were similar to those unselected patients, except that the percentage of children was slightly higher in the selected 
than in unselected group for A(H3N2) samples (Table 1). We speculate that this could be due to small numbers of 
positive specimens in this age group in some weeks.
Among 366 sequenced strains during 2013–2014, the proportion of amino acid mutations of the HA1 poly-
peptide for A(H1N1)pdm09 and A(H3N2) was 1.8–6.5% and 1.1–4.5%, respectively. During the study period, the 
maximum proportion of amino acid mutation per week remained at a relatively low level for subtype A(H1N1)
pdm09, but a clear increasing trend was observed for A(H3N2) (Fig. 2).
In the HI tests, over 99% of the isolates had HI titre over 320 for both A(H1N1)pdm09 and A(H3N2), sug-
gesting that no obvious antigenic variants were detected in this study. There were no statistically significant dif-
ferences in HI titres across age groups of ≤ 18 yrs, 18 to 65 yrs, and ≥ 65 yrs [A(H1N1)pdm09 p = 0.420; A(H3N2) 
p = 0.798]. No gender difference was found in HI titres [A(H1N1)pdm09 p = 0.304; A(H3N2) p = 0.294] 
(Table 2). For genetic variations, no statistically significant differences were found across different age or gender 
groups, in terms of amino acid mutations (Table 2).
Two phylogenetic trees of the HA1 polypeptide sequences from all the A(H1N1)pdm09 and A(H3N2) 
sequences collected in this study, together with representative strains downloaded from the GISAID EpiFlu™ 
databank are shown in Supplementary Information. The phylogenetic tree of A(H1N1)pdm09 was separated into 
eight major genetic clades7. All of the A(H1N1)pdm09 strains that were isolated in this study belong to the clade 
6 and 7 with a signature substitution of S220T in HA1 polypeptide. Mutations P100S, D114N, S220T, R240Q, 
and I338V were observed in over 90% of these A(H1N1)pdm09 isolates. Similarly, all the A(H3N2) isolates fell 
into the clade 3 and 4. There were 7 fixed amino acid mutations (H9Y, Q49R, N161S, Q172H, V202G, Y235S, and 
N294K) detected in nearly all the A(H3N2) strains (Table 3).
Discussion
Influenza A viruses are characterized by a high mutation rate2. Particularly, HA1 polypeptide exhibited higher 
sequence variations than HA2, which may be due to selection pressure from the immune system8–10. Previous 
studies had reported that 1% and 0.8% of amino acids in HA1 domain changed per year for H1 and H3, respec-
tively11. In our study, although genetic variants were frequently detected, none of these genetic variants were 
identified as antigenic drift strains from the vaccine composition strains of A/California/07/2009 (H1N1) and 
A/Victoria/361/2011 (H3N2) recommended during the same season. These findings were consistent with those 
reported by USCDC that over 90% of A(H1N1)pdm09 and A(H3N2) strains isolated in the 2013–14 season were 
similar to the vaccine component strains12. Interestingly, an antigenic drift strain A/Switzerland/9715293/2013 
(H3N2) appeared since January 2015 and caused a relatively severe winter epidemic13. Later WHO recom-
mended this new strain as the vaccine composition strain for A(H3N2) in the 2015–2016 season for the Southern 
Hemisphere14. We further compared our sample strains with this new emerging strain and found that some of our 
sample strains clustered with the A/Switzerland/9715293/2013 (H3N2) into the sub-clade 3C.3 (see phylogenetic 
tree (b). in Supplementary Information). Our findings of an increasing trend in A(H3N2) mutation rates echo the 
findings of Shih and colleagues15. They also suggested that antigenic change of HA1 appears to be ongoing most 
of the time with occasional large changes. However, a mutation confers limited antigenic drift and its frequency 
Figure 1. Weekly numbers of collected samples (blue) and those selected for sequencing (red), 2013–2014. 
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increases only to a low level in the majority of cases, so that a linear increasing trend of mutations, possibly due 
to slow accumulation process, may be observed. These findings suggest that the influenza viruses evolve in a 
gradual process, and mutations at some critical sites that gain the ability of escape from the prior immunity could 
be crucial for emergence or migration of novel strains into Hong Kong. A future study with a longer study period 
using our systematic sampling approach could shed more light on whether influenza viruses in Hong Kong evolve 
through persistent local transmission or repeated introduction from the temperate regions.
Sub-type (Year) Characteristic
Selected case Unselected case
p-value*number (%)
A(H1N1)pdm09
 2013 Total specimens 67 (100%) 172 (100%)
Age (years) 0.86
≤ 18 36 (49%) 98 (57%)
19–64 20 (23%) 50 (29%)
≥ 65 11 (28%) 24 (14%)
Male 35 (52%) 83 (48%) 0.68
 2014 No. of patients 45 (100%) 207 (100%)
Age (years) 0.14
≤ 18 22 (49%) 73 (35%)
19–64 15 (33%) 71 (34%)
≥ 65 8 (18%) 63 (30%)
Male 23 (51%) 105 (51%) 0.91
A(H3N2)
 2013 Total specimens 116 (100%) 240 (100%)
Age (years) 0.001
≤ 18 53 (46%) 67 (28%)
19–64 23 (20%) 45 (19%)
≥ 65 40 (34%) 128 (53%)
Male 65 (56%) 116 (48%) 0.21
 2014 No. of patients 138 (100%) 309 (100%)
Age (years) < 0.001
≤ 18 56 (41%) 65 (21%)
19–64 28 (20%) 55 (18%)
≥ 65 54 (39%) 189 (61%)
Male 73 (53%) 154 (50%) 0.62
Table 1.  Comparison of demographic characteristics of selected and unselected samples by season.  
* Pearson’s Chi-square tests.
Figure 2. Weekly maximum proportion of amino acid mutations for A(H1N1)pdm09 and A(H3N2), 
2013–2014. 
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Our findings further demonstrated the genetic variability of the influenza A viruses after the pandemic in 
200916,17. Most A(H1N1)pdm09 isolates obtained during 2013 to 2014 belong to the clade 6 and 7 (see phy-
logenetic tree (a). in Supplementary Information). This echoes the previous findings of the co-circulation of 
these clades and high genetic diversity of influenza virus A(H1N1)pdm09 during the 2009–2013 seasons7,18,19. 
Mutations of P100S, D114N, S202T, S220T, and I338V had frequently been identified in temperate regions includ-
ing China, France, and Canada, as well as in tropical region of Cuba and Thailand in the same period, whereas 
R240Q mutation was reported for the first time18,20–23. The A(H3N2) strains isolated in Hong Kong during 
2013–2014 fell into the A/Victoria/361/2011 genetic clade, and particularly into the clade 3. 97.6% (248/254) of 
sequences were closely related to the sub-clade 3C and similar to A/Florida/21/2013 strain. The rest (6/254) were 
grouped into the sub-clade 3B, which were similar to A/Mahajanga/3628/2012 strain (see phylogenetic tree (b). in 
Supplementary Information). Mutations Q49R, N161S, Q172H, V202G, Y235S, and N294K were also reported in 
other countries20–22,24. To our surprise, although genetic changes of influenza viruses were continuously observed, 
none of them appeared antigenic variants from the vaccine composition strains. This could be due to the rela-
tively short study period and antigenic variants emerging at the end of the period could have been missed. Future 
studies with intensive collection of sequence data over a longer period, together with more knowledge on the 
association of genetic and antigenic changes, could make possible the development of a forecast model on newly 
emerging antigenic variants. Several models have been adopted to predict influenza virus activity, such as the 
Seasonal Autoregressive Integrated Moving Average (SARIMA) model, Poisson model and SIR model, but most 
of these only consider environmental factors as the drivers for influenza seasonality25–29. Our previous study in 
Hong Kong also demonstrated that the switch of influenza seasonality from one-peak to two-peak patterns coin-
cided with emergence of new A(H3N2) strains, suggesting a link between antigenic change and flu seasonality30. 
Therefore, one future direction of forecast model development could be incorporation of epidemiological and 
molecular data, similar to those collected in this study, in more sophisticated mathematical models.
Subtype No. of samples
Dilution of antiserum in HI tests
p-value*
Genetic variations (Amino acid mutations)
p-value#160 320 640 ≥1280 Mean±SD
H1N1
Age (years) 0.42 0.265
≤ 18 0 1 11 13 9.34 ± 1.79
19–64 0 1 12 8 10.49 ± 3.55
≥ 65 0 1 7 2 9.63 ± 1.01
Male 0 0 15 10 0.304 9.50 ± 2.23 0.276
Female 0 3 15 13 10.00 ± 2.62
H3N2
Age (years) 0.798 0.136
≤ 18 0 8 14 7 10.11 ± 2.59
19–64 1 5 7 4 9.79 ± 2.57
≥ 65 0 7 10 9 10.66 ± 2.48
Male 0 14 15 12 0.294 10.13 ± 2.54 0.451
Female 1 6 16 8 10.38 ± 2.59
Table 2.  Comparison of haemagglutinin inhibition test results and HA1 amino acid mutations 
of A(H1N1)pdm09 and A(H3N2) samples across age and gender, against the reference strains A/
California/07/2009 (H1N1) and A/Victoria/361/2011 (H3N2). * Fisher exact tests. #One-way ANOVA.
Subtype Antigenic site
Original amino 
acid substitution
New amino acid 
substitution
Mutated strains 
number (percent)
H1N1
100 P S 111 (99.11)
114 D N 103 (91.96)
202 S T 103 (91.96)
220 S T 112 (100)
240 R Q 111 (99.11)
338 I V 110 (98.21)
H3N2
9 H Y 250 (98.43)
49 Q R 249 (98.03)
161 N S 247 (97.24)
172 Q H 248 (97.64)
202 V G 253 (99.61)
235 Y S 252 (99.21)
294 N K 252 (99.21)
Table 3.  Common amino acid substitutions observed in antigenic sites of HA1 polypeptide of A(H1N1)
pdm09 and A(H3N2) influenza virus isolates, Hong Kong, 2013–2014.
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Our study also investigated age and gender differences in antigenic and genetic variations. Previous studies 
demonstrated that the A(H1N1)pdm09 virus was associated with an age shift towards young people31,32. But 
inconsistent patterns of gender differences were found across different regions. A study conducted in Australia 
found more fatal cases were male33 while a Canadian study reported that the relative risk of influenza associated 
deaths in adult women is 1.5 times the risk in men34. Some studies observed relatively higher hospitalization 
risks associated with seasonal influenza A(H3N2) in older men than older women although the difference was 
not statistically significant35,36. Boys were found to have a weaker immune response against influenza infections 
than girls37, but this gender difference gradually vanished when they grow into adulthood38. In this study we did 
not find any significant differences across age and gender groups in genetic and antigenic variants of influenza 
A virus. We have previously analyzed age-specific sentinel surveillance data of laboratory confirmed influenza 
in Hong Kong, and found highly synchronized influenza seasonal epidemics across age groups in terms of the 
seasonal patterns, epidemic timing and durations5. Previous studies proposed that influenza seasonal variations 
could be driven by seasonal change of environmental factors (temperature, humidity, etc.), host immunity and 
antigenic change of viruses25,39. Hence this study provides more evidence to support the age synchrony in anti-
genic evolution of influenza viruses, which could partially explain the findings of our previous ecological study. 
Furthermore, our study has exemplified the plausibility of collecting individual demographical data during lab-
oratory surveillance, and a better understanding could be achieved on age and gender synchrony of influenza 
infections when such data become available in a wider range.
There are several limitations in our study. First, the majority of samples were taken from inpatients admitted 
into two public hospitals. However, there is no strong evidence to suggest that influenza A viruses circulating 
in the community are different from those isolated from inpatients40,41. Second, we only sequenced the HA1 
polypeptide of HA due to the limited budget. However, HA2 polypeptide of HA, neuraminidase (NA) and other 
proteins could also affect the genetic and antigenic characteristics of influenza A viruses, which have not been 
explored in this study. Third, HI tests are often criticized for its low sensitivity as compared to other tests such as 
micro-neutralization tests, which might lead to relatively low efficiency in detecting antigenic variants. Fourth, 
there are other available measurements for antigenic distance, such as antigenic maps which requires pairwise HI 
tests across different reference strains. However, given the high titres in HI tests, it is unlikely to observe obvious 
differences between these newly isolated strains if multiple reference strains are used. When potential antigenic 
variants appear in future studies, more sensitive tests and additional reference strains should be considered.
In conclusion, by using an age-stratified random selection strategy, we detected some genetic variants in Hong 
Kong, but no obvious antigenic variants from the WHO vaccine strains during the study period of 2013 to 2014. 
Further studies are warranted to integrate both antigenic profiles of locally circulating strains and other factors, 
allowing us to gain a better understanding on the mechanism of seasonal influenza epidemics.
Materials and Methods
Sample collection. The microbiology laboratory of Queen Mary Hospital routinely collects the nasopharyn-
geal aspirates (NPA) or nasopharyngeal swabs (NPS) from patients who are admitted into two tertiary hospitals 
(Queen Mary Hospital and Pamela Youde Nethersole Eastern Hospital) in Hong Kong Island, with influenza like 
symptoms (temperature > 38 °C, cough and/or sore throat). These two public hospitals accept approximately 
80% of all hospitalizations in Hong Kong Island which has a total population of one million42. Both NPA and 
NPS specimens were divided into two aliquots for direct immunofluorescence (IF) test and RT-PCR respectively. 
Direct IF D3 Ultra 8 DFA respiratory virus screening and identification kit (Diagnostic Hybrid, OH) was used 
to detect antigens of the specimens, and then viewed at a magnification of 400 under epifluorescent illumination 
of an Eurostar III plus (EUROIMMUN AG, Lübeck, Germany) fluorescence microscope43. Influenza A positive 
specimens were subsequently sub-typed into A(H3N2) and A(H1N1)pdm09 by RT-PCR44. Each week up to five 
influenza A positive specimens were selected for genetic sequencing between January 2013 to December 2014. 
If there were more than two positive isolates for each of two subtypes A(H1N1)pdm09 or A(H3N2), two were 
randomly selected from the subtype with less total number of positive specimens and three from the other. If one 
or two positive specimens were found for one subtype in that week, all of them were selected, and the rest were 
from the other subtype to get a total of five specimens. If there were five or less positive specimens in one week, 
all of them were selected. This selection procedure is shown in Fig. 3. In order to assess the age difference, posi-
tive specimens were randomly selected from different age groups of ≤ 18 yrs, 18 to 65 yrs, and ≥ 65 yrs, if any. For 
example, if there were three specimens to be selected from A(H3N2) positive specimens from three age groups, 
one would be randomly selected from each age group. If there were only two age groups, then one extra sample 
would be selected from the age group with more positive specimens. If there were five or less positive specimens 
in one week, all of them would be selected. Because in some weeks there were few or zero positive specimens 
isolated in some age groups, age distribution might be different between selected and unselected specimens due 
to the high chance of being selected in these age groups.
The selected A(H1N1)pdm09 and A(H3N2) positive specimens were then isolated by cell culture on MDCK 
cells45, and subsequently sequenced using the Big Dye Terminator v3.1 Cycle Sequencing Kit. Only HA1 poly-
peptide was sequenced because mutations frequently occur in this polypeptide. It contains 329 amino acids, of 
which131 are located at or close to five antibody epitopes and are the critical sites determining the virus antigenic-
ity10,46. Bioedit version 7.2.5 was used to assemble and edit sequences (http://www.mbio.ncsu.edu/bioedit/bioedit.
html). We chose the representative isolates which had mutations identified from genetic sequencing, for further 
hemagglutinin-inhibition (HI) tests. The reference strains used in the HI tests were A/California/07/2009 (H1N1) 
and A/Victoria/361/2011 (H3N2), which were WHO recommended vaccine composition strains in the 2012/13 
and 2013/14 seasons for the Northern Hemisphere. The HI tests started with 1:10 dilution of antiserum and the 
HI titre less than 40 was regarded as the threshold to define the antigenic variants47. Phylogenetic trees were 
produced by the G T R + G + Γ model of amino acid substitutions incorporated in the MrBayes v.3.2.5 software 
www.nature.com/scientificreports/
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and visualized with the FigTree v.1.4.248. These gene sequences were compared with a sample of gene sequences 
that had been globally isolated in recent years, from the GISAID EpiFlu database (http://www.platform.gisaid.
org) (Table S1). These reference strains selected from the database were representative of the major genetic clades 
defined by WHO7.
During the study period of January 1st, 2013 to December 31st, 2014, a total of 2,115 patients admitted to the 
two public hospitals in Hong Kong Island presented with influenza like symptoms (temperature > 38 °C, cough 
and/or sore throat). Of these, 491 were confirmed infected with A(H1N1)pdm09 and 803 with A(H3N2). We ran-
domly selected 366 positive specimens for sequencing [112 A(H1N1)pdm09 positive and 254A(H3N2) positive]. 
56 of A(H1N1)pdm09 and 72 of A(H3N2) sequenced specimens with potential meaningful point mutations were 
further selected for HI test.
Statistical analysis. Genetic variation was measured by the proportion of amino acid mutations of the HA1 
polypeptide relative to the reference strains, for A(H1N1)pdm09 and A(H3N2) subtypes, respectively21. The pro-
portion of amino acid mutations was defined as
=
.
prop of aa mutation
No of a o acid changes in HA
between sample strain and referencce strain
Total no of HA a o acids
min 1
1 min (1)
Antigenic variation was assessed by the HI tests against the reference strains. The Fisher exact tests were used 
to compare the rates across age and gender groups. In this study statistical significance was defined as p < 0.05. 
Statistical analyses were performed using R software version 3.0.049.
Ethical approval for this study was obtained from the Institutional Review Board of the University of Hong 
Kong/Hospital Authority Hong Kong West Cluster (Reference Number: UW 11-290). Informed consent was 
obtained from all subjects. All experiments were carried out in accordance with the approved guidelines.
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